Association of Angiotensin-Converting Enzyme (ACE) and Glutathione S-Transferase (GST) Gene Polymorphisms with Diabetic Nephropathy

Syed Tasleem Raza, Ale Eba, Sachendra P. Singh, Syed Tahseen Raza*, Farzana Mahdi
Department of Biochemistry, Department of Physiology*
Integral University, Lucknow, Uttar Pradesh, India*
Era's Lucknow Medical College & Hospital, Sarfarazganj, Hardoi Road, Lucknow, U. P., India-226003

ABSTRACT

Diabetic nephropathy accounts for the most serious microvascular complication of diabetes mellitus. It is suggested that the prevalence of diabetic nephropathy will continue to increase in future pretense a major challenge to the healthcare system resulting in increased morbidity and mortality. It occurs as a result of interaction between both genetic and environmental factors in individuals with T2DM-Type 2 diabetes mellitus. Genetic susceptibility has been offered as an important factor for the development of diabetic nephropathy, and various research efforts are being executed worldwide to identify the susceptibility gene for diabetic nephropathy. Several single nucleotide polymorphisms have been found in various genes giving rise to various gene variants which have been found to play a role in genetic susceptibility to diabetic nephropathy. The risk of developing diabetic nephropathy is increased several times by inheriting risk alleles at susceptibility loci of various genes like ACE, GST, TNF-α, COL4A1, eNOS, GLUT, etc. The identification of these genetic variants at a biomarker level could thus, let the detection of those individuals at high risk for diabetic nephropathy which could thus help in the treatment, diagnosis and early prevention of the disease. The present review discusses about the ACE-Angiotensin Converting Enzyme and GST-Glutathione S Transferase gene variants associated with diabetic nephropathy.

KEYWORDS: ACE, GST, Genetic polymorphisms, Diabetic nephropathy

INTRODUCTION

T2DM is a complex syndrome prominent to various metabolic dysfunctions. These metabolic dysfunctions apparent characteristic long-term complications in the form of various microvascular diseases, including diabetic nephropathy, retinopathy, and neuropathy. Diabetic nephropathy is one of the major secondary complications of diabetes mellitus affecting almost 40% of the diabetic patients. Diabetic nephropathy is clinically characterized by proteinuria, declining glomerular filtration rate, hypertension ultimately leading to renal failure, requiring dialysis or transplantation. Various risk factors like, hyperglycemia, increased blood pressure, and genetic alterations may prompt an individual to diabetic nephropathy in the near future (1). It is now a scientifically verified fact that apart from the above risk factors, there is a strong association between an individual's genetic make-ups in his predisposition to diabetic nephropathy. In this context, Andersen et al (2) have shown that 35% of the patients with T2DM develop nephropathy, irrespective of glycemic control. Identification of genetic components of diabetic nephropathy is the most important area of diabetes research because interpretation of genes (alleles) associated with diabetic nephropathy will influence all efforts toward an understanding of the disease at molecular and mechanistic levels, its related complications, cure, treatment and prevention. Association studies of candidate genes for diabetic nephropathy are being conducted all around the globe to identify the biomarkers genes which may predispose a diabetic individual to the risk of diabetic nephropathy. Among the genetic factors involved, single nucleotide polymorphisms in the genes associated with diabetic nephropathy was found to have a major impact on the disease outcome. These gene polymorphisms studies are thus conducted to identify at-risk patients and design therapeutic strategies to prevent the outcome of such complication in his later future.

Developmental Risk Factor of Diabetic Nephropathy

Before the widespread aggressive treatment of blood pressure and hyperglycemia, between 25% and 40% of T2DM patients developed diabetic nephropathy over the course of 25 years and risk factors that differentiate this subgroup from patients who maintain normal renal function are systemic hypertension, glycaemic control, gender (M>F), genetic factors, hyperlipidaemia, dietary protein intake and smoking.

Predictors of Diabetic Nephropathy

On the other hand, most recent studies have abortive to
glomerular filtration rates (GFR) The ACE is a key hyper filtration and hyper perfusion increase dissimilar renal function changes with glomerular can progress to macroalbuminuria (9). DN in progress manifested with microalbuminuria that consequently increase glomerular filtration rates (GFR). DN is glomerular hyper filtration and hyper perfusion progress dissimilar renal function changes with polymorphisms in diabetic nephropathy(8). DN in connecting result related to the role of ACE allele is differentiated might and ethnic group putting decline of GFR in T2DM (7). The frequency of ACE an increased risk of diabetic nephropathy and a rapid DD(Deletion/Deletion) genotype to be associated with in diabetic nephropathy. Some studies have found the nephropathy. Genetic factors are likely to be important in the development of DN, while segregation analyses point to the survival of susceptibility and have established that the onset and progression of DN are inclined genetically (5-6).

**Strategies for identifying susceptibility genes**

There has been incomplete success in identifying genetic variants that modify the hazard of developing diabetic nephropathy. In view of the complication involved, it is not surprising that although investment of significant resources. Both have led to the discovery of many chromosomal and gene regions that may confer susceptibility to Diabetic Nephropathy have been two strategies commonly used to identify Diabetic Nephropathy susceptibility loci: one is linkage analysis another is association analysis. The study of familial clustering of the disease powerfully suggests that genetic factors are implicated in the development of DN, while segregation analyses point to the survival of susceptibility and have established that the onset and progression of DN are inclined genetically (5-6).

**Angiotensin converting enzyme (ACE) gene Polymorphisms**

Angiotensin converting enzyme (ACE) gene is one of the most studied gene to be occupied in the pathogenesis of diabetic nephropathy as well as micro- and macro-albuminuria and development from micro- to macro-albuminuria. The above polymorphism is one of the most calculated polymorphism in diabetic nephropathy. Genetic factors are likely to be important in diabetic nephropathy. Some studies have found the DD(Deletion/Deletion) genotype to be associated with an increased risk of diabetic nephropathy and a rapid decline of GFR in T2DM (7). The frequency of ACE allele is differentiated might and ethnic group putting connecting result related to the role of ACE polymorphisms in diabetic nephropathy(8). DN in progress dissimilar renal function changes with glomerular hyper filtration and hyper perfusion increase glomerular filtration rates (GFR). DN is manifested with microalbuminuria that consequently can progress to macroalbuminuria (9). DN in progress dissimilar renal function changes with glomerular hyper filtration and hyper perfusion increase glomerular filtration rates (GFR) The ACE is a key feature of rennin angiotensin system (RAS) that play critical role in blood pressure homeostasis. In patients who build up macroalbuminuria, there is a progression from micro- to macro-albuminuria, decline of renal function and hypertension (10). Due to the control of genetic factors and metabolic control in pathogenesis of DN-Diabetic Nephropathy, its development varies among diabetic patients (11) The role of ACE I/D(Insertion/Deletion) polymorphism growth of DN to ESRD (End Stage Renal Disease) in T2DM patient has been well-known by a latest meta-analysis (12) create protective role for the D allele of ACE touching diabetic nephropathy.

**Glutathione S - Transferase gene polymorphisms**

In the family of GST enzyme are articulated as dissimilar isofrom coded by a selection genes isolatedmostly on different chromosome (13). Additionally most of these genetic loci accepted to have polymorphic genes (14). A few studies have exposed that polymorphisms of GST genes lead to modify in the appearance of the enzyme, either qualitatively or quantitatively (15) and hence can provide individuals prone to a range of diseases including CKD (Chronic Kidney Disease). Along with all the genetic polymorphisms described in this class of enzymes, the GSTM1 and GSTT1 are most considerable because these genes are reported to be deleted consequential in lack of the exacting isofroms of the enzyme. Studies on Indians, while few, show an elevated prevalence of these the occurrence of GSTM1 and GSTT1 double deletion with nephropathy (16). The association of GSTM1 and GSTT1 deletions with nephropathy (17). (Glutathione S- Transferase mu1 and Glutathione S- Transferase theta1). A current study on Indian population evaluating the association between GST gene polymorphism and susceptibility to end stage renal disease (ESRD) initiates significant relationship of disease (ESRD) initiates with both GSTM1 null and GSTT1 null genotypes with ESRD- End Stage Renal Disease (18). The polymorphic GST gene with respect to diabetic nephropathy initiates that GSTM1 and GSTT1 double deletion seems to have a protective role on the susceptibility to expansion of nephropathy in patients with T2DM. GSTM1 and GSTT1 double deletion appears to be a risk factor for development of nephropathy in T2DM.

**DISCUSSION**

Diabetic nephropathy is actually the most common cause of kidney failure. It is now a scientifically proven fact that there is a strong association between an individual's genetic makeup in his predisposition
to diabetic nephropathy. Multiple genes are involved in pathogenesis of diabetic nephropathy, with several allelic polymorphisms having demonstrable effects in the development and progression of the disease thus contributing to the overall risk. Elhawary NA et al (19) show that the polymorphism of the ACE gene is not significantly associated with diabetic nephropathy in Egyptian ethnicity, while HadjadjS et al (20), Parchwani DN et al (21) in their studies show that ACE gene is significantly associated with DN in France and West Indian ethnicity. Apart from this the prevalence of GSTM1 and GSTT1 null variants have been shown to be remarkably high in different population groups from all over the globe. Studies on Indians, although few, show a high prevalence of these genetic variants in normal population. Studies in the area of diabetic nephropathy are not only few but also inconsistent in their results. While Fujita et al (18) found no association of GSTM1 deletion with diabetic nephropathy in Japanese T2DM patients and Orlewski J et al (22) also found the same in Poland ethnicity; Yang et al (23) showed that GSTT1 null genotype was a risk factor for development of diabetic nephropathy in the Chinese. Kim et al (16) found that GSTM1 null genotype is associated with development of nephropathy in Type 2 diabetes in the Korean population (table 1).

CONCLUSION

This review is based on the study of ACE I/D and GST gene polymorphisms in various populations and it was found that GST gene polymorphisms are not associated with onset and progression of diabetic nephropathy while conflicting results from various studies reported to the association of ACE I/D polymorphism in the development of Diabetic Nephropathy.

| S. No. | Gene | Ethnicity | Case/Control (n) | Significance | References |
|-------|------|-----------|-----------------|--------------|------------|
| 1.    | ACE  | France    | 1057/1127       | Y            | [22]       |
| 2.    |      | West India| 309             | Y            | [21]       |
|       |      | (Gujrat)  |                 |              |            |
| 3.    | GST  | Egyptian  | 220/60          | N            | [23]       |
| 1.    |      | Japanese  |                 | N            | [18]       |
| 2.    |      | Poland    | 874/966         | N            | [20]       |
| 3.    |      | Chinese   |                 | N            | [19]       |
| 4.    |      | Korean    |                 | Y            | [16]       |

n: Numbers, Y: Yes, N: NO

REFERENCES

1. Bowden DW. Genetics of diabetes complications. Curr Diab Rep 2002;2: 191-200
2. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983; 25: 496-501
3. Leehey DJ, Kramer HJ, Daoud TM, Chatha MP, Isreb MA. BMC Nephrol 2005 Jun; 28; 6:8.
4. Boright AP, Paterson AD, Mirea L, et al. Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 2005; 54: 1238–1244
5. Jacobsen PK. Preventing end-stage renal disease in diabetic patients—dual blockade of the renin-angiotensin system (Part II). J Renin Angiotensin Aldosterone Syst 2005; 6: 55–68
6. Felehgari V, Rahimi Z, Mozafari H, Vaisi-Raygani A. ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. Mol Cell Biochem 2011; 346(1-2):23-30.
7. Yoshida H, Kuriyama S, Atsumi Y, et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996; 50: 657-64
8. Chawla T, Sharma D, Singh A. Role of the renin angiotensin system in diabetic nephropathy. World J diabetes 2010; 1(5):141-5.
9. Rahimi Z, Vaisi-Raygani A, Rahimi Z, Parsian A. The concomitant presence of eNOS 894T and ACE D alleles are associated with diabetic nephropathy in Kurdish population from Western Iran. Nephrology (Carlton) 2012; 17(2):175-81.
10. Rahimi M, Hasanvand A, Rahimi Z, Vaisi-Raygani A, Mozafari H, et al. Synergistic Effects of the MTHFR C677T and A1298C polymorphisms on the increase risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. ClinBiochem 2010; 43(16-17):1333-9.
11. Yu ZY, Chen LS, Zhang LC, Zhou TB. Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. Nephrology (Carlton) 2012; 17(5):480-7.
12. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. Glutathione S-transferase family of enzymes. Mut Res / Fundamental and molecular
mechanisms of mutagenesis 2001;482: 21-26.

13. Seidegard J, Vorachek WR, Pero RW, Pearson WR. Hereditary differences in the expression of human glutathione transferase activity on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 1998; 85: 7293-7297.

14. Zhong SL, Zhou SF, Chen X, et al. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. European J Pharm Sci 2006; 28: 77-85.

15. Singh S, Kumar V, Thakur S, et al. Genetic polymorphism of glutathione S-transferase M1 and T1 in Delhi population of Northern India. Environ Toxicol Pharmacol 2009; 28: 25-29.

16. Kim JH, Moon MK, Kim SW, et al. Glutathione S-transferase M1 gene polymorphism is associated with type 2 diabetic nephropathy. J Korean Diabetes Assoc 2005; 29: 315-321.

17. Agrawal S, Tripathi G, Khan F, Sharma R, Baburaj VP. Relationship between GSTs gene polymorphism and susceptibility to end stage renal disease among North Indians 2007; Ren Fail 29: 947-953.

18. Fujita H, Narita T, Meguro H, et al. No association of glutathione S-transferase M1 gene polymorphism with diabetic nephropathy in Japanese. Type 2 diabetic patients. Ren Fail 2000; 22: 479-486.

19. Elhawary NA, Bogari N, Rashad M, Tayeb MT. The Egyptian Journal of Medical Human Genetics 2011; 12, 187–192.

20. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, et al. J Am Soc Nephrol 2007; (4): 1284-91. Epub.

21. Parchwani DN, Palandurkar KM, Kumar DHC, Patel DJ. Indian J Clin Biochem. 2015 Jan; 30(1): 43–54.

22. Orlewski J, Orlewska E. Pol Arch Med Wewn 2015; 125(9): 649-58. Epub 2015 Aug 7.

23. Yang Y, Kao MT, Chang CC, Chung SY, Chen CM, Tsai JJ, Chang JG. Int J Mol Med 2004; Nov; 14(5): 855-9.